Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy

Annals of Clinical and Laboratory Science

Volumn 37, Issue 4, 2007, Pages 343-348

  Shor, Renana ^a   Wainstein, Julio ^a   Oz, David ^a   Boaz, Mona ^a   Matas, Zipora ^a   Fux, Asora ^a   Halabe, Aaron ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

LDL cholesterol; Malignancy; Oxidized LDL; Sepsis

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEPSIS;

AGED; CAUSALITY; CHOLESTEROL, LDL; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEPSIS;

EID: 36148989553     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Roulean JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEJM 2004;350:1495-1504.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-239.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEJM 2005;352:1425-1435.
4. Rossouw JE, Lewis B, Eifkind BM. The value of lowering cholesterol after myocardial infarction. NEJM 1990;323:1112-1119.
5. Oliver MF. Might treatment of hypercholesterolaemia increase noncardiac mortality? Lancet 1991;337:1529-1531.
6. Davey Smith G, Pakkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-434.
7. Law MR, Thompson SG, Wald NJ. Assessing possible hazard of reducing serum cholesterol. BMJ 1994;308:373-379.
8. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, MeMillan G, Neaton J, Nelson J, Potter J, Rifkind B. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-1060.
9. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ 1994;308:367-372.
10. Muldoon MF, Mnuck SB, Matthews KA. Lowering cholesterol concentration and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-314.
11. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions and therapeutic applications. Shock 2004;21:210-221.
12. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation: an inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999;37:777-787.
13. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-488.
14. Netea MG, Demacker PN, Kullberg BJ, Boerman OC, Verschueven I, Stalenhoef AF, Van der Meer JW. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest 1996;97:1366-1372.
15. Vreugdenhil AC, Snoek AM, Van't Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endoxin-LDL/VLDL interaction. J Clin Invest 2001;107:225-234.
16. Bone RC, Black RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
17. Baigent C, Keech PM, Blackwell L, Keamay PM, Buck G, Pillicino C, Kirby A, Sourjina T, Peto R, Collins R, Simer R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
18. Standberg T, Pyorala K, Cook TJ, Wilhemsen L, Faergeman O, Thorgeirsson G, Pederson TR, Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-777.
19. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J Am Coll Cardiol 2007;50:409-418.
20. Berbee JF, Havekes LM, Rensen PC. Apoliporoteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005;11:97-103.
21. Frauberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock 1998;10:359-363.
22. Lelli JL, Drongowski RA, Gastman B, Remick DG, Coran AG. Effects of coenzyme Q10 on the mediator cascade of sepsis. Circ Shock 1993;39:178-187.
23. Suzuki H. Superoxide production of polymorphonuclear leukocytes in endotoxin shock and antioxidative effect of coenzyme Q10. Nippon Ika Daigaku Zasshi 1991;58:236-242.
24. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye LJ, Tanagaawa H. Lovastatin decreases coenzyme Q levels in humans. PNAS USA 1990;87:8931-8934.
25. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-229.
26. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Ouinn PJ. Plasma coenzyme Q (ubiquinone) concentration in patients treated with simvastatin. J Clin Pathol 1993;46:1055-1057.
27. Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Phrmacother 2007;41:647-652.
28. Fiaschi AI, Cozzolino A, Ruggiero G, Giorgi G. Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma. Eur Rev Med Pharmacol Sci 2005;9:361-367.
29. Gonenc A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue malignant breast tumor and benign breast disease. Cell Biol Int 2006;30:376-380.
30. Yeh CC, Hou MF, Tsai SM, Lin SK, Hsiao JK, Huang JC, Wang LH, WU SH, Hou LA, Tsai LY. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 2005;361:104-111.
31. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213-1232.